FDA Warns on Anaphylaxis With IV Rolapitant for CINV FDA Warns on Anaphylaxis With IV Rolapitant for CINV
The drug is used to prevent and reduce chemotherapy-induced nausea and vomiting (CINV) in patients with cancer; anaphylactic reactions have been seen in the postmarketing setting.News Alerts
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Alert Source Type: news
More News: Allergy | Allergy & Immunology | Anaphylactic Shock | Cancer | Cancer & Oncology | Chemotherapy | Hematology